rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Hurco Companies, Inc.

HURC · Nasdaq

Health CareLife-science toolsLeading

HURC stood above a rising 150-day average in 22 of the last 52 weekly readings, including each of the last 19 weeks. It is 7.2% above that average now. Life Science Tools & Research Services: 52% of its 79 stocks in an uptrend (+4 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Leading
Weeks in an uptrend
19 in a row
Industry in uptrend
52% +4 in 4 wk
Insider buys, 12 months
$9,600
Insider sales, 12 months
$0
Officials’ trades on record
1
Institutions holding
56 (+7)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 22 of 52 weeks.

17 Apr – 16 Oct
26%41%57%Apr 26Jun 26Jul 26Sep 26Oct 26

Life-science tools: About half its stocks are in an uptrend and the share has been climbing. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$230K$0$241KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

1 disclosed lines: House 1, Senate 0, executive 0; 1 people.

WhoDidAmountTraded
Debbie Wasserman Schultz House: U.S. House ClerkFL25solddependent child$1k–$15k6 Feb 2025filed 6 Mar 2025

Insiders

Buy orders, 12 months1
Sale orders, 12 months0
Buyers · sellers1 · 0
WhoDidSharesTraded
Janaki SivanesanDirectorbought300at $16.001 Dec 2025filed 19 Feb 2026
Janaki SivanesanDirectorbought550at $16.503 Sep 2025filed 19 Feb 2026
Janaki SivanesanDirectorbought600at $16.503 Sep 2025filed 19 Feb 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders56+7 on the quarter
New · exited10 · 3
Reported value$97.8M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Oppenheimer & Close, LLCadded · filed 12 Aug 2026460,214$10.5M+3,034+0.7%
BRANDES INVESTMENT PARTNERS, LPreduced · filed 14 Aug 2026417,517$9.6M-173,889−29.4%
Brooklands Fund Management Ltdunchanged · filed 11 Aug 2026354,068$7.8M00.0%
DIMENSIONAL FUND ADVISORS LPreduced · filed 11 Aug 2026316,214$7.2M-30,524−8.8%
AMERIPRISE FINANCIAL INCadded · filed 14 Aug 2026305,234$7.0M+34,200+12.6%
Peapod Lane Capital LLCadded · filed 27 Jul 2026264,792$6.1M+19,924+8.1%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026259,917$6.0M+4,797+1.9%
Meros Investment Management, LPreduced · filed 14 Aug 2026211,318$4.8M-221−0.1%
IFP Advisors, Incunchanged · filed 20 Jul 2026200,068$4.6M00.0%
Pacific Ridge Capital Partners, LLCreduced · filed 12 Aug 2026169,747$3.9M-1,314−0.8%
31 Mar 2023 – 30 Jun 2026
434955Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Benjamin Rashleger Company insiderDirector · last 12 Mar 20260 · 0
Cynthia S. Dubin Company insiderDirector · last 12 Mar 20260 · 0
Janaki Sivanesan Company insiderDirector · last 12 Mar 20267 · 0
Lawrence Keyler Company insiderDirector · last 12 Mar 20260 · 0
Michael Doar Company insiderDirector · last 12 Mar 20265 · 12
Richard R. Porter Company insiderDirector · last 12 Mar 20263 · 3
Timothy J. Gardner Company insiderDirector · last 12 Mar 20260 · 0
Gregory S. Volovic Company insiderPresident & CEO · last 7 Jan 20262 · 6
HaiQuynh Jamison Company insiderCorporate Controller · last 7 Jan 20263 · 0
Jonathon D. Wright Company insiderGeneral Counsel/Corp Secretary · last 7 Jan 20262 · 0
Sonja K. McClelland Company insiderChief Financial Officer · last 7 Jan 20262 · 2
Polar Asset Management Partners Inc. Company insider10% owner · last 28 Mar 20250 · 11

Same industry

OABI OmniAbLeading+65%
TXG 10x GenomicsLeading+60%
AVTR AvantorLeading+47%
ILMN IlluminaLeading+44%
RVTY RevvityLeading+37%
MASS 908 DevicesLeading+31%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Oct 202518.5%
Operating profit marginFY 2025 · to 31 Oct 2025-5.8%
Free cash flow marginFY 2025 · to 31 Oct 20259.3%
Return on capital employedFY 2025 · to 31 Oct 2025-4.8%
Research spendFY 2025 · to 31 Oct 20252.2%
Share count trendFY 2025 · to 31 Dec 20250.2%
Cash and equivalentsFY 2025 · to 31 Oct 2025$48.7M
Free cash flowFY 2025 · to 31 Oct 2025$16.7M

Analyst forecasts

No analyst forecasts yet.